Cargando…
Efficacy and safety of immune checkpoint inhibitor monotherapy in elderly patients with non‐small cell lung cancer
The efficacy and safety of immune checkpoint inhibitor (ICI) monotherapy in elderly patients with non‐small cell lung cancer (NSCLC) remain unclear, especially in patients older than 80 years. We retrospectively reviewed the records of 10 patients older than 80 years with NSCLCs treated by ICIs. The...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954839/ https://www.ncbi.nlm.nih.gov/pubmed/33738379 http://dx.doi.org/10.1002/agm2.12147 |
_version_ | 1783664158827347968 |
---|---|
author | Chikaishi, Yasuhiro Inoue, Masaaki Kusanagi, Kasumi Honda, Yohei Yoshida, Junichi Tanaka, Masao |
author_facet | Chikaishi, Yasuhiro Inoue, Masaaki Kusanagi, Kasumi Honda, Yohei Yoshida, Junichi Tanaka, Masao |
author_sort | Chikaishi, Yasuhiro |
collection | PubMed |
description | The efficacy and safety of immune checkpoint inhibitor (ICI) monotherapy in elderly patients with non‐small cell lung cancer (NSCLC) remain unclear, especially in patients older than 80 years. We retrospectively reviewed the records of 10 patients older than 80 years with NSCLCs treated by ICIs. The median age was 85 years (range, 82‐93 years), and 7 patients were men. The median length of follow‐up was 13 months (range, 4.5‐23 months). Eight patients had adenocarcinoma (3 of whom had exon 19 deletions), and two had squamous cell carcinoma. Expression of programmed cell death ligand 1 (PD‐L1) was ≥ 50% in 3 patients, between 1% and 49% in 4 patients, < 1% in 1 patient, and undetected in 2 patients. Patients with undetected PD‐L1 underwent transbronchial lung biopsy. Performance status was graded zero, one, and two in two, seven, and one patients, respectively. First‐, second‐, and third‐line treatments were administered to three, three, and four patients, respectively. The 2‐year overall survival rate was 30.0% (median, 285 days). Time to treatment failure rate on the 2 years was 10.0% (median, 167 days). One patient achieved a partial response, and one achieved a complete response. ICI‐associated adverse events occurred in five patients. In summary, ICIs were effective in some patients older than 80 years; however, some experienced adverse effects. Elderly patients must be selected carefully for ICI treatment. |
format | Online Article Text |
id | pubmed-7954839 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79548392021-03-17 Efficacy and safety of immune checkpoint inhibitor monotherapy in elderly patients with non‐small cell lung cancer Chikaishi, Yasuhiro Inoue, Masaaki Kusanagi, Kasumi Honda, Yohei Yoshida, Junichi Tanaka, Masao Aging Med (Milton) Short Communication The efficacy and safety of immune checkpoint inhibitor (ICI) monotherapy in elderly patients with non‐small cell lung cancer (NSCLC) remain unclear, especially in patients older than 80 years. We retrospectively reviewed the records of 10 patients older than 80 years with NSCLCs treated by ICIs. The median age was 85 years (range, 82‐93 years), and 7 patients were men. The median length of follow‐up was 13 months (range, 4.5‐23 months). Eight patients had adenocarcinoma (3 of whom had exon 19 deletions), and two had squamous cell carcinoma. Expression of programmed cell death ligand 1 (PD‐L1) was ≥ 50% in 3 patients, between 1% and 49% in 4 patients, < 1% in 1 patient, and undetected in 2 patients. Patients with undetected PD‐L1 underwent transbronchial lung biopsy. Performance status was graded zero, one, and two in two, seven, and one patients, respectively. First‐, second‐, and third‐line treatments were administered to three, three, and four patients, respectively. The 2‐year overall survival rate was 30.0% (median, 285 days). Time to treatment failure rate on the 2 years was 10.0% (median, 167 days). One patient achieved a partial response, and one achieved a complete response. ICI‐associated adverse events occurred in five patients. In summary, ICIs were effective in some patients older than 80 years; however, some experienced adverse effects. Elderly patients must be selected carefully for ICI treatment. John Wiley and Sons Inc. 2021-01-29 /pmc/articles/PMC7954839/ /pubmed/33738379 http://dx.doi.org/10.1002/agm2.12147 Text en © 2021 The Authors. Aging Medicine published by Beijing Hospital and John Wiley & Sons Australia, Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Short Communication Chikaishi, Yasuhiro Inoue, Masaaki Kusanagi, Kasumi Honda, Yohei Yoshida, Junichi Tanaka, Masao Efficacy and safety of immune checkpoint inhibitor monotherapy in elderly patients with non‐small cell lung cancer |
title | Efficacy and safety of immune checkpoint inhibitor monotherapy in elderly patients with non‐small cell lung cancer |
title_full | Efficacy and safety of immune checkpoint inhibitor monotherapy in elderly patients with non‐small cell lung cancer |
title_fullStr | Efficacy and safety of immune checkpoint inhibitor monotherapy in elderly patients with non‐small cell lung cancer |
title_full_unstemmed | Efficacy and safety of immune checkpoint inhibitor monotherapy in elderly patients with non‐small cell lung cancer |
title_short | Efficacy and safety of immune checkpoint inhibitor monotherapy in elderly patients with non‐small cell lung cancer |
title_sort | efficacy and safety of immune checkpoint inhibitor monotherapy in elderly patients with non‐small cell lung cancer |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954839/ https://www.ncbi.nlm.nih.gov/pubmed/33738379 http://dx.doi.org/10.1002/agm2.12147 |
work_keys_str_mv | AT chikaishiyasuhiro efficacyandsafetyofimmunecheckpointinhibitormonotherapyinelderlypatientswithnonsmallcelllungcancer AT inouemasaaki efficacyandsafetyofimmunecheckpointinhibitormonotherapyinelderlypatientswithnonsmallcelllungcancer AT kusanagikasumi efficacyandsafetyofimmunecheckpointinhibitormonotherapyinelderlypatientswithnonsmallcelllungcancer AT hondayohei efficacyandsafetyofimmunecheckpointinhibitormonotherapyinelderlypatientswithnonsmallcelllungcancer AT yoshidajunichi efficacyandsafetyofimmunecheckpointinhibitormonotherapyinelderlypatientswithnonsmallcelllungcancer AT tanakamasao efficacyandsafetyofimmunecheckpointinhibitormonotherapyinelderlypatientswithnonsmallcelllungcancer |